Everything below concerns C18 column. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-14. Numbers and descriptions here follow the published literature rather than marketing material.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
=== Cerebrospinal fluid (lumbar puncture) === Testing of cerebrospinal fluid obtained from a lumbar puncture can provide evidence of chronic inflammation in the central nervous system. Two different biomarkers can show this inflammation with similar accuracy:
Anabolism is the set of constructive metabolic processes where the energy released by catabolism is used to synthesize complex molecules. In general, the complex molecules that make up cellular structures are constructed step-by-step from smaller and simpler precursors. Anabolism involves three basic stages. First, the production of precursors such as amino acids, monosaccharides, isoprenoids and nucleotides, secondly, their activation into reactive forms using energy from ATP, and thirdly, the assembly of these precursors into complex molecules such as proteins, polysaccharides, lipids and nucleic acids. Anabolism in organisms can be different according to the source of constructed molecules in their cells. Autotrophs such as plants can construct the complex organic molecules in their cells such as polysaccharides and proteins from simple molecules like carbon dioxide and water. Heterotrophs, on the other hand, require a source of more complex substances, such as monosaccharides and amino acids, to produce these complex molecules. Organisms can be further classified by ultimate source of their energy: photoautotrophs and photoheterotrophs obtain energy from light, whereas chemoautotrophs and chemoheterotrophs obtain energy from oxidation reactions.
Level 1: COMP (exons 10–15) and MATN3 (exon 2) Level 2: COMP (exons 8 & 9 and 16–19) Level 3: COL9A1 (exon 8), COL9A2 and COL9A3 (exon 3) All those genes are involved in the production of the extracellular matrix (ECM). The role of COMP gene remains unclear. It is a noncollagenous protein of the ECM. Mutations in this gene can cause the pseudoachondroplasia (PSACH). It should play a role in the structural integrity of cartilage by its interaction with other extracellular matrix proteins and can be part of the interaction of the chondrocytes with the matrix and it is also a potent suppressor of apoptosis in chondrocytes. Another role is maintaining a vascular smooth muscle cells contractile under physiological or pathological stimuli. Since 2003, the European Skeletal Dysplasia Network has used an online system to diagnose cases referred to the network before mutation analysis to study the mutations causing PSACH or MED. COL9A1, COL9A2, COL9A3 are genes coding for collagen type IX, that is a component of hyaline cartilage. MATN3 protein may play a role in the formation of the extracellular filamentous networks and in the development and homeostasis of cartilage and bone. In the recessive form, the DTDST gene, also known as SLC26A2, is mutated in almost 90% of the patients, causing diastrophic dysplasia. It is a sulfate transporter, transmembrane glycoprotein implicated in several chondrodysplasias. It is important for sulfation of proteoglycans and matrix organization.
== Veterinary use == Tapentadol has been demonstrated as a potentially effective analgesic in experimental studies however, further research is needed before it can be recommended for clinical use. Tapentadol is mainly metabolized as tapentadol-O-glucuronide in dogs and tapentadol-O-sulfate in cats. Intravenous, but not oral, administration has been shown to be effective in the dog, inducing sedation, salivation, ataxia, diarrhoea, and thermal antinociception. In cats intravenous, intramuscular, and subcutaenous administration has resulted in mild sedation and salivation. IV produced longer and greater sedation in the cat than IM and SC.
The rates of azoospermia increased with greater CPA dosage, which was attributed to the additional AR antagonism of higher doses of CPA. Significant spermatogenesis still occurs with 50 mg/day CPA alone, but spermatogenesis is significantly reduced compared to normal. At a dosage of 200 mg/day, CPA has been found to produce azoospermia (sperm count of less than 1 million/mL) in men within 8 to 10 weeks of treatment. However, fertility is generally lost even at a lower dosage of CPA of 100 mg/day because there is complete inhibition of the accessory sex glands and hence an absence of semen production and ejaculate upon orgasm. Ejaculate volume decreases at a dosage of 50 mg/day and decreases to almost zero after 6 weeks of high-dose CPA therapy. The effects of CPA on fertility are completely reversible. This has been demonstrated in clinical studies of male adolescents and adults treated with CPA continuously for 6 to 7 years.
Sources: en.wikipedia.org
1 July Gerard Cott, 83, politician, TD (1969–1973). John O'Grady, 83, hurling referee. 3 July – Greig Oliver, 58, rugby union coach (Munster, national under-20 team). Born in Scotland. 6 July Brendan Daly, 83, politician, TD (1973–1992 and 1997–2002), Minister for the Marine (1987–1989), Minister for Social Welfare (1991–1992). Roly Meates, 85, rugby union player (Dublin University Football Club, Wanderers) and coach (Leinster, national team). 10 July – Ben Briscoe, 89, politician, TD (1965–2002) and Lord Mayor of Dublin (1988–1989). 22 July – Bill Cashin, 85, politician, Senator (1993–1997). 26 July – Sinéad O'Connor, 56, singer-songwriter. 28 July – Flor O'Mahony, 77, politician, Senator (1981–1987) and MEP (1983–1984). 30 July – Frank Rodgers, 82, Gaelic footballer (Beragh Red Knights, Tyrone senior team) and administrator. 31 July – Jimmy Cooney, 68, hurler (Sarsfields, Galway senior team) and referee.
Prior to widespread use of air-conditioning, salt shakers with caps containing silica gel beads to keep the salt dry enough to prevent clumping were marketed in the US, replacing the practice of including a few grains of rice in salt shakers to effect the same drying. Silica gel is sometimes used as a preservation tool to control relative humidity in museum and library exhibitions and storage. Other applications include diagnostic test strips, inhalation devices, syringes, drug test kits, and hospital sanitation kits. Silica gel is commonly described as a way to remove moisture from phones and electronics accidentally exposed to water, but there are no known controlled studies that compare its actual efficacy compared to simple air or fan exposure. The average person is also unlikely to have a sufficient quantity of ready-to-use activated or regenerated silica gel.
=== Superabsorbent polymers === One area of aspartic acid market growth is biodegradable superabsorbent polymers (SAP), and hydrogels. Around 75% of superabsorbent polymers are used in disposable diapers and an additional 20% is used for adult incontinence and feminine hygiene products. Polyaspartic acid, the polymerization product of aspartic acid, is a biodegradable substitute to polyacrylate.
=== House of Representatives === In 1968, Mizell was elected to represent the 5th District in the 91st United States Congress. He defeated Democratic nominee Smith Bagley, an R.J. Reynolds Tobacco Company official, 84,905 (52.4 percent) to 77,112 (47.6 percent). The previous 5th District representative, Democrat Nick Galifianakis, was moved to the 4th District for the 1968 elections. A supporter of Richard Nixon, Mizell ran on a platform vehemently opposed to federal spending and Communism. In his first term, he spoke in favor of trade legislation. "I believe no nation in the world need fear the Trade Bill of 1970," he said, praising it for its benefits to foreign nations and American workers alike.
synonymous mutation Also synonymous substitution or samesense mutation. A type of mutation in which the substitution of one nucleotide base for another results, after transcription and translation, in an amino acid sequence which is identical to the original unmutated sequence. This is possible because of the degeneracy of the genetic code, which allows different codons to code for the same amino acid. Though synonymous mutations are often considered silent, this is not always the case; a synonymous mutation may affect the efficiency or accuracy of transcription, splicing, translation, or any other process by which genes are expressed, and thus become effectively non-silent. Contrast nonsynonymous mutation.
Sources: en.wikipedia.org
Techniques have been developed to produce nanotubes in sizeable quantities, including arc discharge, laser ablation, chemical vapor deposition (CVD) and high-pressure carbon monoxide disproportionation (HiPCO). Among these arc discharge, laser ablation are batch by batch process, Chemical Vapor Deposition can be used both for batch by batch or continuous processes, and HiPCO is gas phase continuous process. Most of these processes take place in a vacuum or with process gases. The CVD growth method is popular, as it yields high quantity and has a degree of control over diameter, length and morphology. Using particulate catalysts, large quantities of nanotubes can be synthesized by these methods, and industrialisation is well on its way, with several CNT and CNT fibers factory around the world. One problem of CVD processes is the high variability in the nanotube's characteristics. The HiPCO process advances in catalysis and continuous growth are making CNTs more commercially viable. The HiPCO process helps in producing high purity single-walled carbon nanotubes in higher quantity. The HiPCO reactor operates at high temperature 900–1100 °C and high pressure ~30–50 bar. It uses carbon monoxide as the carbon source and iron pentacarbonyl or nickel tetracarbonyl as a catalyst. These catalysts provide a nucleation site for the nanotubes to grow, while cheaper iron-based catalysts like Ferrocene can be used for CVD process. Vertically aligned carbon nanotube arrays are also grown by thermal chemical vapor deposition.
==== Knight Grand Cross of the Royal Victorian Order (GCVO) ==== The Most Reverend and Right Honourable Justin Portal Welby, Archbishop of Canterbury, on the occasion of the Coronation of Their Majesties The King and The Queen.
In recent years, several successful FCA claims related to CLIA have opened a new avenue of regulatory liability for laboratories and provided a financial incentive for whistleblowers. Historically, laboratory compliance issues have primarily been viewed as billing issues, but increasingly, quality-of-care issues are receiving attention, as whistleblower lawsuits allege substandard or poor-quality testing, which is actionable under the False Claims Act as "worthless service." An improper proficiency testing (PT) referral may result in an FCA claim under the "false certification" theory. In 2011, a medical technologist filed an FCA claim under the "worthless services" theory against the Mimbres Memorial Hospital in Deming, New Mexico, alleging that routine quality control for microbiology was not performed per CLIA and that the hospital knowingly released and billed for non-verifiable results before the department was shut down. In 2013, the United States District Court for the District of New Mexico dismissed the FCA claim since maintaining compliance with a CLIA Certificate of Compliance (CoC) was not a condition of payment under Medicare, only a condition of participation. In 2020, an FCA claim against DaVita was filed under the "implied false certification" theory, alleging that specimens from around the country were shipped to Florida, where DaVita maintained its laboratories for tax benefits, under poorly controlled environmental conditions and without validating those storage conditions. The case settled. In 2021, an oncology clinic in St.
=== Unit name === In 1993, the IUPAC proposed the shorter name "dalton" (with symbol "Da") for the unified atomic mass unit. As with other unit names such as watt and newton, "dalton" is not capitalized in English, but its symbol, "Da", is capitalized. The name was endorsed by the International Union of Pure and Applied Physics (IUPAP) in 2005. In 2003 the name was recommended to the BIPM by the Consultative Committee for Units, part of the CIPM, as it "is shorter and works better with [SI] prefixes". In 2006, the BIPM included the dalton in its 8th edition of the SI brochure of formal definitions as a non-SI unit accepted for use with the SI. The name was also listed as an alternative to "unified atomic mass unit" by the International Organization for Standardization in 2009. It is now recommended by several scientific publishers, and some of them consider "atomic mass unit" and "amu" deprecated. In 2019, the BIPM retained the dalton in its 9th edition of the SI brochure, while dropping the unified atomic mass unit from its table of non-SI units accepted for use with the SI, but secondarily notes that the dalton (Da) and the unified atomic mass unit (u) are alternative names (and symbols) for the same unit.
With the tearing down of the Berlin Wall and with East and West Germany pursuing re-unification, the Iron Curtain between the West and Soviet-occupied regions came down. By 1989, the Soviet alliance system was on the brink of collapse, and, deprived of Soviet military support, the communist leaders of the Warsaw Pact states were losing power. Grassroots organizations, such as Poland's Solidarity movement, rapidly gained ground with strong popular bases.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.